Evans AS - Search Results

1

Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer.

Adams M, Borysiewicz L, Fiander A, Man S, Jasani B, Navabi H, Lipetz C, Evans AS, Mason M. Adams M, et al. Among authors: evans as. Vaccine. 2001 Mar 21;19(17-19):2549-56. doi: 10.1016/s0264-410x(00)00488-6. Vaccine. 2001. PMID: 11257391 Review.

2

A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.

Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, Evans AS, Adams M, Stacey SN, Boursnell ME, Rutherford E, Hickling JK, Inglis SC. Borysiewicz LK, et al. Among authors: evans as. Lancet. 1996 Jun 1;347(9014):1523-7. doi: 10.1016/s0140-6736(96)90674-1. Lancet. 1996. PMID: 8684105 Clinical Trial.

3

Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes.

Evans EM, Man S, Evans AS, Borysiewicz LK. Evans EM, et al. Among authors: evans as. Cancer Res. 1997 Jul 15;57(14):2943-50. Cancer Res. 1997. PMID: 9230206

4

Clinical studies of human papilloma vaccines in cervical cancer.

Adams M, Borysiewicz L, Fiander A, Man S, Jasani B, Navabi H, Evans AS, Mason M. Adams M, et al. Among authors: evans as. Adv Exp Med Biol. 2001;495:419-27. doi: 10.1007/978-1-4615-0685-0_61. Adv Exp Med Biol. 2001. PMID: 11774604 No abstract available.

5

Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R).

Adams M, Navabi H, Jasani B, Man S, Fiander A, Evans AS, Donninger C, Mason M. Adams M, et al. Among authors: evans as. Vaccine. 2003 Jan 30;21(7-8):787-90. doi: 10.1016/s0264-410x(02)00599-6. Vaccine. 2003. PMID: 12531360 Review.

6

Immunocompetent for immunotherapy? A study of the immunocompetence of cervical cancer patients.

Fiander AN, Adams M, Evans AS, Bennett AJ, Borysiewicz LK. Fiander AN, et al. Among authors: evans as. Int J Gynecol Cancer. 1995 Nov;5(6):438-442. doi: 10.1046/j.1525-1438.1995.05060438.x. Int J Gynecol Cancer. 1995. PMID: 11578518

7

Cytotoxic T cell immunity to human cytomegalovirus glycoprotein B.

Hopkins JI, Fiander AN, Evans AS, Delchambre M, Gheysen D, Borysiewicz LK. Hopkins JI, et al. Among authors: evans as. J Med Virol. 1996 Jun;49(2):124-31. doi: 10.1002/(SICI)1096-9071(199606)49:2<124::AID-JMV9>3.0.CO;2-7. J Med Virol. 1996. PMID: 8991935

8

Generation of in vitro autologous human cytotoxic T-cell response to E7 and HER-2/neu oncogene products using ex-vivo peptide loaded dendritic cells.

Navabi H, Jasani B, Adams M, Evans AS, Mason M, Crosby T, Borysiewicz L. Navabi H, et al. Among authors: evans as. Adv Exp Med Biol. 1997;417:583-9. doi: 10.1007/978-1-4757-9966-8_94. Adv Exp Med Biol. 1997. PMID: 9286422 No abstract available.

9

Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6.

Evans M, Borysiewicz LK, Evans AS, Rowe M, Jones M, Gileadi U, Cerundolo V, Man S. Evans M, et al. Among authors: evans as. J Immunol. 2001 Nov 1;167(9):5420-8. doi: 10.4049/jimmunol.167.9.5420. J Immunol. 2001. PMID: 11673561

10

A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group.

Adams M, Kerby IJ, Rocker I, Evans A, Johansen K, Franks CR. Adams M, et al. Acta Oncol. 1989;28(1):57-60. doi: 10.3109/02841868909111182. Acta Oncol. 1989. PMID: 2650722 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

288 results

Search Page